Albireo Pharma Inc. (ALBO) Fundamentals

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
SHARE INFORMATION
Market Cap$ 492,276,510
Shares Outstanding20,701,283
Float15,846,140
Percent Float76.55%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 40,579,000
Latest Fiscal EPS$ -1.86
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions282
Institutional Holdings Date2022-11-30
Institutional Bought Previous 3 Months1,867,691
Institutional Holdings Percent140.9%
Institutional Sold Previous 3 Months3,209,792
Insider Holdings Date2022-11-30
Insider Bought Previous 3 Months-
Insider Holdings Percent19.7
Insider Sold Previous 3 Months423,134
Insider Shares Owned4,072,662
TRADING INFO
52 Week High$ 37.63
52 Week Low$ 16.02
52 Week High Change$ 0.9766
21 Day Moving Average$ 21.9305
21 Day Extended Moving Average$ 21.9674
50 Day Moving Average$ 21.0806
50 Day Extended Moving Average$ 21.3163
200 Day Moving Average$ 24.089
200 Day Extended Moving Average$ 23.1474
10 Day Average Volume116,115
20 Day Average Volume176,359
30 Day Average Volume173,682
50 Day Average Volume273,096
Alpha0.000543
Beta0.8166
Standard Deviation0.139112
R20.097561
7 Day Price Change$ 1.77
7 Day Percent Change8.04%
21 Day Price Change$ 2.47
21 Day Percent Change11.59%
30 Day Price Change$ 1.38
30 Day Percent Change6.16%
Month to Date Price Change$ 1.70
Month to Date Percent Change7.7%
Quarter to Date Price Change$ 4.42
Quarter to Date Percent Change22.83%
180 Day Price Change$ 3.97
180 Day Percent Change20.04%
200 Day Price Change$ -4.26
200 Day Percent Change-15.19%
Year to Date Price Change$ 0.49
Year to Date Percent Change2.1%

Albireo Pharma Inc. (ALBO) Key Ratios

PROFITABILITY
EBIT Margin-215.2%
EBITDA Margin-214.5%
Pre-Tax Profit Margin-484,510.7%
Profit Margin Count-80.9%
Gross Margin95.6%
Profit Margin TOT-80.9%
INCOME STATEMENTS
Revenue$ 57,391,000
Revenue Per Share$ 2.7723
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book5.90
Total Debt To Equity0.10
Int Coverage-10.80
Current Ratio6.30
Leverage Ratio2.10
Quick Ratio5.90
Long Term Debt To Capital0.06
VALUATION MEASURES
PE Ratio-3.50
Enterprise Value$ 321,463,509
Price to Sales8.5776
Price to Free Cash-4.20
PE High Last 5 Years-1.60
Price To Book4.90
Price To Cash Flow0.00
PE Low Last 5 Years-6.00
Price to Tangible Book5.90
MANAGEMENT EFFECTIVENESS
Receivables Turnover34.40
Invoice Turnover1.50
Assets Turnover0.10
Return Assets-42.46
Return on Equity-93.08
Return on Capital-84.98

Albireo Pharma Inc. (ALBO) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEORonald H.W. Cooper
Emplyoees130
Last AuditUQ
CIK0001322505
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address53 State Street
19th Floor
Boston, MA 2109
Websitehttps://www.albireopharma.com
Facsimile-
Telephone+1 857 254-5555
Emailmedinfo@albireopharma.com


Your Recent History
NASDAQ
ALBO
Albireo Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.